本文選題：前列腺癌 + 骨轉(zhuǎn)移　； 參考：《南昌大學(xué)》2017年碩士論文

【摘要】：目的:通過免疫組化、PCR技術(shù)探討B(tài)RAF基因在前列腺癌骨轉(zhuǎn)移與無骨轉(zhuǎn)移中的表達(dá)差異,并分析BRAF突變基因與前列腺癌骨轉(zhuǎn)移之間的相關(guān)性。方法:(1)隨機(jī)選取南昌大學(xué)第一附屬醫(yī)院2013年01月~2015年02月期間在我科經(jīng)前列腺穿刺活檢或手術(shù)后病理檢查確診的103例前列腺癌患者以及同時期隨機(jī)選取20例前列腺良性增生患者作為研究對象,以ECT、CT/MRI或骨活檢診斷骨轉(zhuǎn)移,前列腺癌的臨床分期根據(jù)美國腫瘤聯(lián)合會(AJCC,2009年)的TNM分期標(biāo)準(zhǔn)。(2)運(yùn)用免疫組織化學(xué)方法檢測BRAF蛋白在前列腺癌骨轉(zhuǎn)移,前列腺癌無骨轉(zhuǎn)移及前列腺增生組織(前列腺腫瘤組織)中的表達(dá)情況,并分析其意義。(3)運(yùn)用PCR技術(shù)檢測BRAF基因在前列腺癌骨轉(zhuǎn)移、前列腺癌無骨轉(zhuǎn)移及前列腺增生組織(前列腺腫瘤組織)中突變的情況,并分析其意義。(4)利用SPSS19.0軟件系統(tǒng)建立數(shù)據(jù)庫并進(jìn)行統(tǒng)計學(xué)分析,對比研究BRAF突變基因與前列腺癌骨轉(zhuǎn)移的關(guān)系。結(jié)果:1、免疫組化實驗結(jié)果顯示:(1)BRAF蛋白在前列腺癌骨轉(zhuǎn)移和前列腺癌無骨轉(zhuǎn)移組織中的表達(dá),結(jié)果顯示BRAF蛋白在前列腺癌骨轉(zhuǎn)移和前列腺癌無骨轉(zhuǎn)移組織中的表達(dá)差異有統(tǒng)計學(xué)意義(P0.05)。(2)BRAF蛋白在前列腺癌骨轉(zhuǎn)移和前列腺增生組織中的表達(dá),結(jié)果顯示BRAF蛋白在前列腺癌骨轉(zhuǎn)移和前列腺癌增生組織中的表達(dá)差異有統(tǒng)計學(xué)意義(P0.05)。2、PCR實驗結(jié)果顯示:前列腺增生組BRAF基因無突變,前列腺癌骨轉(zhuǎn)移組BRAF基因突變與前列腺癌無骨轉(zhuǎn)移組BRAF基因突變相比較,結(jié)果顯示BRAF基因突變在前列腺癌骨轉(zhuǎn)移和前列腺癌無骨轉(zhuǎn)移組織中的表達(dá)差異有統(tǒng)計學(xué)意義(P0.05)。結(jié)論:前列腺癌骨轉(zhuǎn)移BRAF蛋白的表達(dá)高于前列腺癌無骨轉(zhuǎn)移組和前列腺增生組,前列腺癌骨轉(zhuǎn)移組BRAF基因突變率要明顯高于前列腺癌無骨轉(zhuǎn)移組,初步提示BRAF突變基因可能可以作為一個前列腺癌骨轉(zhuǎn)移患者的相關(guān)因素。
[Abstract]:Objective: to investigate the difference of BRAF gene expression between bone metastases and bone metastases of prostate cancer by immunohistochemical technique and to analyze the correlation between BRAF mutation gene and bone metastasis of prostate cancer. Methods A total of 103 patients with prostate cancer confirmed by biopsy or pathological examination after operation were randomly selected from the first affiliated Hospital of Nanchang University from January 2013 to February 2015, and 20 cases were randomly selected from the same period. Patients with benign hyperplasia of glands were studied. Bone metastases were diagnosed by CT / MRI or bone biopsy. The clinical staging of prostate cancer was based on TNM staging standard of AJCC (2009). Immunohistochemical method was used to detect BRAF protein in bone metastasis of prostate cancer. Expression of BRAF gene in prostate cancer without bone metastasis and prostatic hyperplasia (prostate cancer) and its significance were analyzed. PCR technique was used to detect the expression of BRAF gene in bone metastasis of prostate cancer. The significance of mutation in prostate cancer without bone metastasis and prostatic hyperplasia (prostate cancer tissue) was analyzed, and the database was established by SPSS 19.0 software system and analyzed statistically. To study the relationship between BRAF mutation gene and bone metastasis of prostate cancer. Results the immunohistochemical results showed the expression of BRAF protein in bone metastases of prostate cancer and no bone metastasis in prostate cancer. The results showed that there were significant differences in the expression of BRAF protein between prostate cancer bone metastasis and prostate cancer without bone metastasis. The expression of BRAF protein in prostate cancer bone metastases and prostate hyperplasia tissues was significantly different. The results showed that there was significant difference in the expression of BRAF protein in bone metastases and hyperplasia of prostate cancer. The results of PCR showed that there was no mutation of BRAF gene in benign prostatic hyperplasia. The expression of BRAF gene mutation in bone metastases of prostate cancer was significantly different from that in bone metastases of prostate cancer and no bone metastases of prostate cancer (P 0.05), and the results showed that there was a significant difference in the expression of BRAF gene between the bone metastases of prostate cancer and those without bone metastasis of prostate cancer. Conclusion: the expression of BRAF protein in bone metastases of prostate cancer is higher than that in prostate cancer without bone metastasis and prostatic hyperplasia, and the mutation rate of BRAF gene in prostate cancer bone metastasis is significantly higher than that in prostate cancer without bone metastasis. These results suggest that the BRAF mutation gene may be a related factor in bone metastases of prostate cancer.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 付金倫;陳捷;孫庭;王共先;;Raf蛋白激酶在前列腺癌臟器和骨轉(zhuǎn)移中的研究進(jìn)展[J];南昌大學(xué)學(xué)報(醫(yī)學(xué)版);2016年06期

2 許召良;馬志方;;上皮間質(zhì)轉(zhuǎn)化與前列腺癌[J];國際泌尿系統(tǒng)雜志;2014年04期

3 趙朋;于斌;劉德祥;胡海龍;白鐵男;孫光;;Bcl-2、Ki-67在前列腺癌組織中的表達(dá)及臨床意義[J];天津醫(yī)藥;2013年10期

4 王輝;侯瑞;楊光;徐文林;呂申;;BRAF在前列腺癌組織中的表達(dá)及意義[J];大連醫(yī)科大學(xué)學(xué)報;2010年06期

相關(guān)博士學(xué)位論文 前1條

1 陳棟;BRAF基因突變與惡性腫瘤的系統(tǒng)評價及其痕量檢測方法的構(gòu)建[D];第三軍醫(yī)大學(xué);2014年

相關(guān)碩士學(xué)位論文 前2條

1 張煒浩;TGF-β1、VEGF在前列腺癌臨床分期及冷凍治療前后表達(dá)的臨床意義[D];天津醫(yī)科大學(xué);2014年

2 劉曉艷;前列腺癌中BRAF、Raf1基因改變與蛋白表達(dá)[D];浙江大學(xué);2012年

，

本文編號：1995030